Researchers Develop New Immunotherapy Approaches for Cancer Treatment

Researchers are making significant strides in developing new cancer treatments that focus on empowering the body's own immune system to fight cancer, rather than directly attacking tumors. This includes methods to reprogram immune cells within the body to recognize and attack cancer cells, as well as enhancing the broader immune response through therapies targeting the CD40 receptor. These advancements signal a shift towards more targeted, effective, and accessible cancer care.

Researchers at the University of California, San Francisco, have developed a method to reprogram immune cells within the body to target cancer cells, rather than the current approach of extracting cells, modifying them in a lab, and then re-infusing them. This internal reprogramming technique has shown promising results in studies on mice, including complete remission of some leukemia cases. Additionally, researchers are refining CD40-based therapies that stimulate the immune system's broader response, with recent early-stage clinical trials showing tumor reduction in half of participants and complete remission in two cases.

A recent early-stage clinical trial involving 12 patients with metastatic cancer was conducted to test the CD40-based therapy. The new immunotherapy approaches being developed offer the potential for more personalized, less invasive, and potentially more successful cancer treatments by harnessing the body's natural defenses.

Meanwhile, glioblastoma, the most aggressive primary brain tumor in adults, remains largely unresponsive to today's clinically proven immunotherapies. Despite substantial investment in therapeutic research, the standard of care for glioblastoma—surgical resection followed by radiation and temozolomide—has remained fundamentally unchanged for decades. This disparity reflects the uniquely complex biology of glioblastoma and the structural constraints of the central nervous system.

Conventional monoclonal antibodies, recombinant proteins, cytokines, and even cellular therapies have faced intrinsic limitations when applied to brain tumors. Their limited distribution across the blood-brain barrier, poor persistence in the tumor microenvironment, and vulnerability to antigen loss or immunosuppression illustrate where conventional modalities fall short. However, new trends and capabilities in antibody engineering are beginning to reshape the neuro-oncology landscape.

Advances in protein design, including multispecific constructs, nanobody fusion formats, engineered Fc functions, and precision-tuned binding domains, are enabling researchers to generate therapeutic antibodies that can more effectively reach the central nervous system and overcome persistent barriers to efficacy. Recombinant engineering methods empower researchers to leverage antibodies as modular, reconfigurable biological tools rather than fixed molecular scaffolds, unlocking a wide spectrum of possibilities for next-generation glioblastoma immunotherapies.

The blood-brain barrier restricts entry of nearly all large-molecule biologics, such as antibodies and therapeutic proteins, into the central nervous system. Additionally, the size and hydrophilicity of most biologics also prevent passive diffusion across the barrier. Agents capable of passing the blood-brain barrier are subject to an additional challenge: the barrier contains active efflux transporters, such as P-glycoprotein and multidrug resistance proteins, that pump out drugs and further reduce their concentration in the brain.

Glioblastoma demonstrates significant molecular and cellular heterogeneity, both within a single tumor and between different patients. Surgical resection remains the first-line intervention for glioblastoma, but the invasive nature of the tumor makes complete removal virtually impossible. While gross total resection may improve progression-free survival, microscopic infiltrative cells extend far beyond the enhancing core, making recurrence in nearby tissue common.